Prestige News

Total 67
Number Thumbnail Title Author Date Votes Views
67 Prestige Biopharma IDC Publishes Preclinical Efficacy Results of IDC007 in International Academic Journal
김** | 2026.07.16 | Votes 0 | Views 478
김** 2026.07.16 0 478
66 Prestige Biopharma Unveils Follow-up Clinical Development Strategy for Pancreatic Cancer Drug Candidate PBP1510 at ESMO GI
김** | 2026.07.09 | Votes 0 | Views 919
김** 2026.07.09 0 919
65 Prestige Biopharma IDC Publishes Preclinical Results for Bispecific Antibody IDC007, Targeting Immunotherapy Side Effects
김** | 2026.07.07 | Votes 0 | Views 1036
김** 2026.07.07 0 1036
64 Prestige Biopharma Enters Strategic MOU with Charles River , a Global Contract Research Organization
김** | 2026.07.02 | Votes 0 | Views 1558
김** 2026.07.02 0 1558
63 Prestige Biopharma to Present Clinical Development Strategy for Pancreatic Cancer Candidate at ESMO GI 2026
김** | 2026.06.30 | Votes 0 | Views 1769
김** 2026.06.30 0 1769
62 Prestige Biopharma to Participate in BIO USA 2026, Targeting Global Market Expansion
김** | 2026.06.16 | Votes 0 | Views 1929
김** 2026.06.16 0 1929
61 Prestige Biopharma IDC Selected for Ministry of Health and Welfare’s Advanced Biopharma Convergence Talent Development Program
김** | 2026.06.08 | Votes 0 | Views 1440
김** 2026.06.08 0 1440
60 Prestige Biopharma Outlines Phase 2a Clinical Development Roadmap for Pancreatic Cancer Therapy PBP1510
김** | 2026.06.01 | Votes 0 | Views 1684
김** 2026.06.01 0 1684
59 Prestige Biopharma Expands Global Collaboration Opportunities for Pancreatic Cancer Therapy at ASCO 2026
김** | 2026.05.26 | Votes 0 | Views 1858
김** 2026.05.26 0 1858
58 Prestige Biopharma IDC Signs Joint Research Agreement for Antibody Therapeutic Development Targeting Cancer Cachexia
김** | 2026.05.19 | Votes 0 | Views 1646
김** 2026.05.19 0 1646